Summit Therapeutics Inc.: Leerink Partners raises target price to $13 from $11
SMMT•Leerink Partners raised its target price for Summit Therapeutics to $13 from $11.
Related News
Septerna director Alan Ezekowitz reports sale of $3.93 million in common shares
SEPN•
US to resume flights after air traffic network failure sparks chaos
XLI•
Nasdaq trade halt continues, reason not available at 3:28 a.m.
UCFI•
CrowdStrike CEO George Kurtz reports $6.26 million common-share disposal
CRWD•
Tenet Healthcare director Roy Blunt reports sale of $293,000 in common shares
THC•